Molecular Partners AG
Molecular Partners AG (MLLCF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Molecular Partners AG (MLLCF), featuring income statements, balance sheets, and cash flow data.
Molecular Partners AG (MLLCF) Income Statement & Financial Overview
View the income breakdown for Molecular Partners AG MLLCF across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $681000.00 | $1.55M | $2.74M |
| Cost of Revenue | $0.00 | $0.00 | $13.09M | $14.10M |
| Gross Profit | $0.00 | $681000.00 | -$11.54M | -$11.37M |
| Gross Profit Ratio | $0.00 | $1.00 | -$7.44 | -$4.15 |
| R&D Expenses | $10.55M | $10.86M | $13.09M | $14.10M |
| SG&A Expenses | $3.83M | $4.41M | $3.84M | $3.89M |
| Operating Expenses | $14.79M | $15.27M | $16.92M | $17.99M |
| Total Costs & Expenses | $14.79M | $15.27M | $17.53M | $18.60M |
| Interest Income | $651000.00 | $718000.00 | $912000.00 | $1.10M |
| Interest Expense | $9000.00 | $9000.00 | $6000.00 | $7000.00 |
| Depreciation & Amortization | $570000.00 | $591000.00 | $603000.00 | $605000.00 |
| EBITDA | -$10.65M | -$15.80M | -$14.47M | -$10.71M |
| EBITDA Ratio | -$23.21 | -$9.33 | -$3.91 | |
| Operating Income | -$14.79M | -$14.59M | -$15.98M | -$15.86M |
| Operating Income Ratio | -$21.42 | -$10.30 | -$5.79 | |
| Other Income/Expenses (Net) | $3.56M | -$1.81M | $894000.00 | $4.53M |
| Income Before Tax | -$11.23M | -$16.40M | -$15.08M | -$11.32M |
| Income Before Tax Ratio | -$24.09 | -$9.72 | -$4.14 | |
| Income Tax Expense | $2000.00 | $0.00 | $0.00 | $561724.00 |
| Net Income | -$11.23M | -$16.40M | -$15.08M | -$11.32M |
| Net Income Ratio | -$24.09 | -$9.72 | -$4.14 | |
| EPS | -$0.33 | -$0.49 | -$0.45 | -$0.34 |
| Diluted EPS | -$0.33 | -$0.49 | -$0.45 | -$0.34 |
| Weighted Avg Shares Outstanding | $36.86M | $33.19M | $33.18M | $32.87M |
| Weighted Avg Shares Outstanding (Diluted) | $36.86M | $33.19M | $33.18M | $32.87M |
Over the last four quarters, Molecular Partners AG achieved steady financial progress, growing revenue from $2.74M in Q1 2024 to $0.00 in Q4 2024. Gross profit stayed firm with margins at N/A in Q4 2024 versus -415% in Q1 2024. Operating income totaled -$14.79M in Q4 2024, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$10.65M. Net income rose to -$11.23M, with EPS at -$0.33. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan